Kepler Capital analyst Christian Faitz maintained a Hold rating on Bayer (0P6S – Research Report) on January 21 and set a price target of ...

Bayer expects its pharmaceutical business to return to growth in 2027 as the launch new therapies is expected to offset ...

Bayer is facing billions of dollars in exposure from a growing number of lawsuits over PCB products. Read more at ...

These launches are what Oelrich called “must-win battles” at Bayer as the Xarelto loss of exclusivity reaches “full swing” in ...

Bayer said Thursday it has acquired camelina germplasm, intellectual property, and materials from Smart Earth Camelina Corp.

In a report released today, Richard Vosser from J.P. Morgan maintained a Hold rating on Bayer (0P6S – Research Report), with a price target of ...

As leaders gather for the World Economic Forum Annual Meeting 2025 in Davos, Leaps by Bayer, the impact investing arm of ...

Chemical company Monsanto — owned by Bayer — was found liable this week by a jury for harm caused to students and parents at ...

Bayer AG plans to push pause on some of its pharmaceutical dealmaking, focusing instead on reducing the high debt load the ...

Bayer AG faces a $100 million jury verdict over PCB exposure at a Seattle school amid ongoing legal challenges related to toxic chemicals.

Bayer AG was told by a jury to pay $100 million to four people at a Seattle-area school who said their exposure at the facility to toxic chemicals made by the company’s Monsanto unit caused brain ...